An2 Therapeutics Inc's Customers Performance

Name: An2 Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

ANTX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


ANTX's Source of Revenues		• List of ANTX Customers

for the same period An2 Therapeutics Inc

• List of ANTX Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

An2 Therapeutics Inc's Comment on Sales, Marketing and Customers

News about An2 Therapeutics Inc Contracts

AN2 Therapeutics Partners with GSK to Combat Tuberculosis with Innovative Boron-Based Therapies

In a significant advancement in the fight against tuberculosis (TB), AN2 Therapeutics, Inc., a pioneering biopharmaceutical company based in Menlo Park, California, has announced a research collaboration with the global biopharmaceutical giant GlaxoSmithKline (GSK). This partnership aims to develop novel therapies utilizing boron-based leucyl-tRNA synthetase (LeuRS) inhibitors a promising approach in targeting TB, a longstanding global health challenge. Collaboration OverviewThe collaboration agreement with GSK marks a pivotal step for AN2 Therapeutics as they leverage their proprietary boron chemistry platform to create small molecule therapeutics designed specifically to combat TB. This partnership is not ...

AN2 Therapeutics Epetraborole Shows Efficacy in Phase 2 Study for MAC Lung Disease, Paving the Way for Fut...

AN2 Therapeutics Announces Promising Results for Epetraborole in Treating MAC Lung Disease Menlo Park, Calif. AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company renowned for its pioneering efforts in the development of small molecule therapeutics derived from its advanced boron chemistry platform, has made significant strides in the battle against treatment-refractory Mycobacterium avium Complex (MAC) lung disease. In a pivotal announcement, the company unveiled topline results from the Phase 2 segment of its ongoing EBO-301 Phase 2/3 study, which assesses the efficacy of epetraborole when administered alongside an optimized background regimen (OBR). Study OverviewThe EBO-301 study is des...

ANTX's Stock Performance relative to it's Customers

ANTX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
An2 Therapeutics Inc	244.39	1.35	-34.55	21
SUBTOTAL	0.00	0.00	0.00	-

Sources: An2 Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: An2 Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on An2 Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.